Teva Pharmaceutical Industries Ltd. (TEVA) is experiencing a remarkable turnaround, with its stock surging over 100% in the past year, as analysts express renewed optimism. Once burdened by legal challenges and a heavy debt load, Teva has improved its financial standing, with 12 of 13 analysts now rating it a “buy” or “strong buy.” The consensus 12-month price target suggests an additional 11% upside, bolstered by strong sales from its branded drug Austedo and a significant reduction in debt.
The company’s prospects are further enhanced by an upcoming FDA decision on its olanzapine extended-release injectable suspension, which could serve as a key catalyst for growth. Teva’s current valuation, trading at 13 times forward earnings compared to the healthcare sector average of 16.5, positions it attractively for investors seeking value.
While challenges remain, including litigation risks and pricing pressures in its generic-drug business, Teva’s operational improvements and growth trajectory make it a compelling stock to watch in the pharmaceutical sector.
Source: fool.com